Soon Thye Lim, Chief Executive Officer at National Cancer Centre Singapore, shared on LinkedIn:
“Today, we signed a MOU with Suzhou Cancer Hospital, established through a partnership between Junshi Biosciences and Nanjing University. Together, Suzhou Cancer Hospital, NCCS and SGH commit to developing an international hub for cancer diagnosis, treatment and translational medicine, with a focus on nuclear medicine and radiopharmaceuticals. As Singapore’s national specialty centre for cancer care, NCCS is privileged to be part of this collaboration and will contribute expertise in oncology clinical services, joint research, clinical trials and professional development.
I visited the Suzhou Cancer Hospital in November 2025 while it was being constructed and was impressed with their vision to create China’s first closed-loop, full-chain precision medicine diagnosis and treatment centre, integrating radionuclide supply, clinical trials and clinical application. This model is strategic as we enter a new era of cancer care, where radiopharmaceuticals and theranostics will pave the way for more precise diagnosis and treatment. Through this partnership, we will exchange knowledge, evaluate new approaches across different healthcare settings, and contribute evidence that will shape the future of cancer care in Asia.
Looking forward to working with our partners Prof Su Wan, Prof Wang Hongwei, Mr Xiong Jun, Mr Li Ning, Dr Chen Gang, and the teams from Suzhou Cancer Hospital, Junshi Biosciences and SGH!”

You can also read:
SIOG and CACA Establish New Partnership to Take The Geriatric Oncology Mission Global
Suheir Rasul: Celebrating 25 Years of Partnership Between St. Jude and King Hussein Cancer Center